ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

Sun Pharma willing to review deals after insider trading reports

India's biggest drugmaker under scrutiny over $250m loan

According to the company, it had 19 new generic drugs and two new dosages pending approval from Halol for the U.S. market.   © Reuters

MUMBAI -- Top Indian drugmaker Sun Pharmaceutical Industries said it would review some past business dealings to allay worries about its corporate governance following allegations of insider trading.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more